On the stock market since 2014, it operates in the world of health and science. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 66% a year over the last 4 years. Red columns mark years that ended in a loss.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.
An investor who bought at the very peak is down 91% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
A loss of $43K against $71K in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.36. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, EXHI sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: EXHI is a small company that closed last year at a loss. The road back to profit runs through spending discipline.